3171 results for «3221»
3171 results
Therapeutic choices for TTVIV-TTVIR interventions
21 May 2025 – From EuroPCR 2025
Explore therapeutic choices for transcatheter tricuspid valve-in-valve and valve-in-ring interventions. Case studies cover annular ring expansion, pacing-related infection, jugular vein access valve replacement, Ebstein anomaly, and double valve-in-valve procedures in right heart disease.
TAVI in challenging anatomical situations
21 May 2025 – From EuroPCR 2025
Delve into the latest advancements in TAVI for challenging anatomical situations. This session features insights from the NORTHOSTAVI registry, transcaval TAVI experiences, early discharge protocols following alternative access, and the application of intravascular lithotripsy to enable safe transfemoral valve replacement.
Mitral TEER in challenging scenarios - Part 3
21 May 2025 – From EuroPCR 2025
This session focuses on challenging mitral TEER cases, including papillary muscle rupture post-myocardial infarction, advanced heart failure treatment, emerging therapies for mitral regurgitation, and novel percutaneous repair techniques.
Antiplatelet strategies for clinical dilemmas
22 May 2025 – From EuroPCR 2025
Dive into the complexities of antiplatelet strategies tailored for challenging clinical scenarios. This session covers antiplatelet therapy in myocardial bridge, bleeding risk reduction via ticagrelor removal before urgent CABG, peri-procedural management for patients on oral anticoagulants undergoing PCI, and the use of cangrelor in out-of-hospital cardiac...
Novel tools and techniques to manage complex PCI scenarios
22 May 2025 – From EuroPCR 2025
This session introduces novel tools and techniques to manage complex PCI scenarios. Key topics include intravascular lithotripsy advancements for in-stent restenosis, innovative balloon-assisted fenestration of covered stents, long-term outcomes of drug-eluting balloons post directional coronary atherectomy, and safety and efficacy data on a novel high-pressure cutting...
Coronary protection during native and valve-in-valve TAVI
22 May 2025 – From EuroPCR 2025
Understand the critical role of coronary protection during native and valve-in-valve transcatheter aortic valve implantation (TAVI). This session covers procedural planning essentials, the impact of upfront coronary protection, challenges in coronary obstruction diagnosis, and the use of guide catheter extension to facilitate protection during TAVI procedures.
Management of bifurcations with complex anatomy - Part 1
22 May 2025 – From EuroPCR 2025
This session addresses the management of bifurcations with complex anatomy through a series of challenging case studies. It features a traumatic coronary artery dissection, anomalous right coronary artery PCI, CTO interventions complicated by proximal dissection, double CTO PCI for complete revascularization, and a challenging calcified left...
TAVI coronary access
22 May 2025 – From EuroPCR 2025
Gain expertise in managing coronary access challenges in TAVI patients. This session discusses when and how to treat coronary lesions in TAVI candidates, strategies to facilitate coronary approach post-TAVI, and long-term outcomes with practical tips through illustrative cases including primary PCI after CoreValve implantation and valve-in-valve...
How to address the problem of calcified left main lesions
22 May 2025 – From EuroPCR 2025
Gain expert perspectives on addressing calcified left main coronary lesions in high-risk and complex clinical scenarios. This session features challenging cases including ACS patients with reduced LVEF, severe calcified stenosis of left main bifurcation, complex PCI in post-CABG octogenarians with rotablation under Impella support, and other...
When angina cannot be cured with stents: what are the remaining options
22 May 2025 – From EuroPCR 2025
Explore therapeutic options for patients with angina refractory to stenting. This session reviews the efficacy and clinical outcomes of coronary sinus (CS) reducer implantation for microvascular dysfunction, factors influencing procedural success, next-generation CS reducer innovations, and the role of aspirin in angina without obstructive coronary disease.
Management of challenging TAVI device delivery
22 May 2025 – From EuroPCR 2025
Explore innovative solutions for managing challenging TAVI device delivery. This session presents cases involving kinked and stuck Navitor valves, the use of snare devices for retrieval, balloon-expandable TAVI in severe bicuspid aortic stenosis, and alternative access routes such as transaortic access after failed transfemoral valve-in-valve procedures.
Beyond the intervention: outcomes of CTO PCI
22 May 2025 – From EuroPCR 2025
Discover long-term outcomes and practical insights into chronic total occlusion (CTO) PCI. This session presents real-world registry data, cost-effectiveness analyses, effects of successful revascularisation in reduced ejection fraction and heart failure patients, and specific outcomes in octogenarian populations.
TAVI - Outcomes predictors
22 May 2025 – From EuroPCR 2025
Examine novel predictors of outcomes following TAVI. This session compares a new nutritional risk index against traditional scores for early post-TAVI mortality prediction and evaluates uric acid as a marker for aortic valve calcification and mortality risk in TAVI patients.
Optimal acute heart failure care: must have, must do
22 May 2025 – From EuroPCR 2025
This session presents must-have strategies for optimal acute heart failure care. Topics include establishing an extracorporeal cardiopulmonary resuscitation referral center with patient outcomes, percutaneous closure in ventricular septal rupture, modified manual compression for large-bore sheaths, antithrombotic therapy considerations in AMI complicated by cardiogenic shock with mechanical...
Retrograde removal of the broken sheath
22 May 2025 – From EuroPCR 2025
This session addresses complex complications during vascular access with a focus on retrograde removal of broken sheaths. Learn to recognize critical signs, manage rare but severe complications including broken guidewires in the radial artery, and explore innovative off-label solutions for challenging scenarios.
Optimal SCAD treatment
22 May 2025 – From EuroPCR 2025
Navigate the complexities of spontaneous coronary artery dissection (SCAD) treatment through clinical case discussions. This session explores identifying the culprit lesion, recurrent ACS challenges, the conservative versus PCI treatment dilemma, and real-world presentation scenarios emphasizing decision-making in SCAD management.
TAVI for aortic regurgitation off label
22 May 2025 – From EuroPCR 2025
Explore off-label applications of TAVI for aortic regurgitation in complex clinical scenarios. Topics include TAV-in-SAV with Trilogy valve for severe regurgitation, challenges of transcatheter prosthesis in pure aortic regurgitation, management of surgical valve perforations, and treatment strategies in post-surgical anatomies including degenerative homografts and aortic dissection.
PCI in a challenging coronary anatomy
22 May 2025 – From EuroPCR 2025
This session tackles PCI in challenging coronary anatomies, featuring cases with anomalous coronary arteries, complex access routes, and specialized stenting techniques. Learn from experiences managing dual anomalous arteries, navigating to difficult lesions, and applying innovative modified chimney stent methods to restore coronary flow.
Acute complications during distal left main PCI - Part 3
22 May 2025 – From EuroPCR 2025
This session highlights acute complications during distal left main PCI. It presents cautionary cases of incorrect left main stenting, catastrophic left main V stenting outcomes, unprotected left main thrombosis, and survival strategies when new technologies fail unexpectedly.
Innovations in transcatheter aortic valve devices and techniques
22 May 2025 – From EuroPCR 2025
Explore the latest advancements in transcatheter aortic valve devices and innovative procedural techniques. This session presents initial clinical experiences with new self-expandable valves in small annuli, safety and performance data from the GENESIS-II study on the Hydra valve, and up to 12-month outcomes from the Valvosoft...
